MedPath

A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2053

Phase 1
Completed
Conditions
Hyperlipemia
Interventions
Drug: Placebo
First Posted Date
2024-01-29
Last Posted Date
2025-04-04
Lead Sponsor
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Target Recruit Count
39
Registration Number
NCT06229548
Locations
🇨🇳

10 Chedaogou Rd.,Haidian District, Beijing, China, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath